当前位置: 首页 >> 检索结果
401. The RAISE Trial: A Novel Device and First-in-Man Trial.
作者: Wei Sun.;Huayiyang Zou.;Yonghong Yong.;Boxun Liu.;Hao Zhang.;Jieyu Lu.;Yihui Shen.;Peng Li.;Tianhua Xu.;Xuguan Chen.;Anning Du.;Ming Jiang.;Yang Hua.;Yanhui Sheng.;Bin Zhou.;Chaim Lotan.;Xiangqing Kong.
来源: Circ Heart Fail. 2022年15卷4期e008362页
Currently, standard medical therapies have limited effects on heart failure with preserved ejection fraction (HFpEF), which impacts on the life quality and survival of patients. This study aimed to evaluate the safety and efficacy of the percutaneous radiofrequency ablation-based interatrial shunting for HFpEF with a novel atrial septostomy device.
402. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
作者: Mikhail N Kosiborod.;Christiane E Angermann.;Sean P Collins.;John R Teerlink.;Piotr Ponikowski.;Jan Biegus.;Josep Comin-Colet.;João Pedro Ferreira.;Robert J Mentz.;Michael E Nassif.;Mitchell A Psotka.;Jasper Tromp.;Martina Brueckmann.;Jonathan P Blatchford.;Afshin Salsali.;Adriaan A Voors.
来源: Circulation. 2022年146卷4期279-288页
Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 (sodium-glucose cotransporter 2) inhibitors improve health status in chronic heart failure, but their effect on these outcomes in acute heart failure is not well characterized. We investigated the effects of the SGLT2 inhibitor empagliflozin on symptoms, physical limitations, and quality of life, using the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the EMPULSE trial (Empagliflozin in Patients Hospitalized With Acute Heart Failure Who Have Been Stabilized).
403. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study).
作者: Mehdi H Shishehbor.;Thomas Zeller.;Martin Werner.;Marianne Brodmann.;Helen Parise.;Andrew Holden.;Michael Lichtenberg.;Sahil A Parikh.;Vikram S Kashyap.;Cody Pietras.;Daniela Tirziu.;Shiva Ardakani.;Ulrich Beschorner.;Prakash Krishnan.;Khusrow A Niazi.;Andreas U Wali.;Alexandra J Lansky.
来源: Circulation. 2022年145卷22期1645-1654页
First-generation drug-coated balloons (DCBs) have significantly reduced the rate of restenosis compared with balloon angioplasty alone; however, high rates of bailout stenting and dissections persist. The Chocolate Touch DCB is a nitinol constrained balloon designed to reduce acute vessel trauma and inhibit neointima formation and restenosis.
404. Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial.
作者: Duk-Woo Park.;Jung-Min Ahn.;Do-Yoon Kang.;Kyung Won Kim.;Hyun Jung Koo.;Dong Hyun Yang.;Seung Chai Jung.;Byungjun Kim.;Yiu Tung Anthony Wong.;Cheung Chi Simon Lam.;Wei-Hsian Yin.;Jeng Wei.;Yung-Tsai Lee.;Hsien-Li Kao.;Mao-Shin Lin.;Tsung-Yu Ko.;Won-Jang Kim.;Se Hun Kang.;Sung-Cheol Yun.;Seung-Ah Lee.;Euihong Ko.;Hanbit Park.;Dae-Hee Kim.;Joon-Won Kang.;Jae-Hong Lee.;Seung-Jung Park.; .
来源: Circulation. 2022年146卷6期466-479页
It is unknown whether the direct oral anticoagulant edoxaban can reduce leaflet thrombosis and the accompanying cerebral thromboembolic risk after transcatheter aortic valve replacement. In addition, the causal relationship of subclinical leaflet thrombosis with cerebral thromboembolism and neurological or neurocognitive dysfunction remains unclear.
405. Presenting Symptoms in Patients Undergoing Coronary Artery Disease Evaluation: Association With Noninvasive Test Results and Clinical Outcomes in the PROMISE Trial.
作者: Angela Lowenstern.;Karen P Alexander.;Neha J Pagidipati.;C Larry Hill.;Patricia A Pellikka.;Lawton S Cooper.;Brooke Alhanti.;Udo Hoffmann.;Daniel B Mark.;Pamela S Douglas.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷5期e008298页
Patients evaluated for coronary artery disease have a range of symptoms and underlying risk. The relationships between patient-described symptoms, clinician conclusions, and subsequent clinical management and outcomes remain incompletely described.
406. Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome.
作者: James Xu.;Sidney Lo.;Christian J Mussap.;John K French.;Rohan Rajaratnam.;Krishna Kadappu.;Upul Premawardhana.;Phong Nguyen.;Craig P Juergens.;Dominic Y Leung.
来源: Circ Cardiovasc Interv. 2022年15卷4期e011419页
Coronary microvascular dysfunction after acute coronary syndrome is an important predictor of long-term prognosis. Data is lacking on the effects of oral P2Y12-inhibitors on coronary microvascular function in non-ST-segment-elevation acute coronary syndrome. The aim of this study was to compare the acute effects of ticagrelor versus clopidogrel pretreatment on coronary microvascular function in non-ST-segment-elevation acute coronary syndrome patients.
407. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
作者: Brian A Bergmark.;Nicholas A Marston.;Candace R Bramson.;Madelyn Curto.;Vesper Ramos.;Alexandra Jevne.;Julia F Kuder.;Jeong-Gun Park.;Sabina A Murphy.;Subodh Verma.;Wojtek Wojakowski.;Steven G Terra.;Marc S Sabatine.;Stephen D Wiviott.; .
来源: Circulation. 2022年145卷18期1377-1386页
Genetic loss-of-function variants in ANGPTL3 are associated with lower levels of plasma lipids. Vupanorsen is a hepatically targeted antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis.
408. Quality of Life After Fractional Flow Reserve-Guided PCI Compared With Coronary Bypass Surgery.
作者: William F Fearon.;Frederik M Zimmermann.;Victoria Y Ding.;Jo M Zelis.;Zsolt Piroth.;Giedrius Davidavicius.;Samer Mansour.;Rajesh Kharbanda.;Nikolaos Östlund-Papadogeorgos.;Keith G Oldroyd.;Olaf Wendler.;Michael J Reardon.;Y Joseph Woo.;Alan C Yeung.;Nico H J Pijls.;Bernard De Bruyne.;Manisha Desai.;Mark A Hlatky.; .
来源: Circulation. 2022年145卷22期1655-1662页
Previous studies have shown that quality of life improves after coronary revascularization more so after coronary artery bypass grafting (CABG) than after percutaneous coronary intervention (PCI). This study aimed to evaluate the effect of fractional flow reserve guidance and current generation, zotarolimus drug-eluting stents on quality of life after PCI compared with CABG.
409. Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial.
作者: Paolo Della Bella.;Francesca Baratto.;Pasquale Vergara.;Patrizia Bertocchi.;Matteo Santamaria.;Pasquale Notarstefano.;Leonardo Calò.;Daniela Orsida.;Luca Tomasi.;Marcello Piacenti.;Stefano Sangiorgio.;Francesco Pentimalli.;Etienne Pruvot.;João De Sousa.;Frederic Sacher.;Massimo Tritto.;Luca Rebellato.;Thomas Deneke.;Salvo Andrea Romano.;Martina Nesti.;Alessio Gargaro.;Daniele Giacopelli.;Giovanni Peretto.;Andrea Radinovic.
来源: Circulation. 2022年145卷25期1829-1838页
Optimal timing for catheter ablation of ventricular tachycardia is an important unresolved issue. There are no randomized trials evaluating the benefit of ablation after the first implantable cardioverter defibrillator (ICD) shock.
410. Synthetic Extracellular Volume in Cardiac Magnetic Resonance Without Blood Sampling: a Reliable Tool to Replace Conventional Extracellular Volume.
作者: Wensu Chen.;Patrick Doeblin.;Sarah Al-Tabatabaee.;Karin Klingel.;Radu Tanacli.;Karl Jakob Weiß.;Christian Stehning.;Amit R Patel.;Burkert Pieske.;Jiangang Zou.;Sebastian Kelle.
来源: Circ Cardiovasc Imaging. 2022年15卷4期e013745页
The calculation of extracellular volume (ECV) in cardiac magnetic resonance requires hematocrit, limiting its applicability in clinical practice. Based on the linear relationship between hematocrit and blood T1 relaxivity, a synthetic ECV could be estimated without a blood sample. We aim to develop and test regression models for synthetic ECV without blood sampling in 1.5-T and 3.0-T scanners.
411. Feasibility of a Randomized Clinical Trial of Cardiac Resynchronization Therapy With or Without an Implantable Defibrillator in Older Patients.
作者: Andrew D Althouse.;Sandeep Kumar Jain.;Alaa Shalaby.;Madhurmeet Singh.;Raul Weiss.;Larissa Myaskovsky.;Sana M Al-Khatib.;Samir Saba.
来源: Circ Arrhythm Electrophysiol. 2022年15卷4期e010795页 412. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
作者: Barry A Borlaug.;John Blair.;Martin W Bergmann.;Heiko Bugger.;Dan Burkhoff.;Leonhard Bruch.;David S Celermajer.;Brian Claggett.;John G F Cleland.;Donald E Cutlip.;Ira Dauber.;Jean-Christophe Eicher.;Qi Gao.;Thomas M Gorter.;Finn Gustafsson.;Chris Hayward.;Jan van der Heyden.;Gerd Hasenfuß.;Scott L Hummel.;David M Kaye.;Jan Komtebedde.;Joseph M Massaro.;Jeremy A Mazurek.;Scott McKenzie.;Shamir R Mehta.;Mark C Petrie.;Marco C Post.;Ajith Nair.;Andreas Rieth.;Frank E Silvestry.;Scott D Solomon.;Jean-Noël Trochu.;Dirk J Van Veldhuisen.;Ralf Westenfeld.;Martin B Leon.;Sanjiv J Shah.; .
来源: Circulation. 2022年145卷21期1592-1604页
In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit.
413. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.
作者: Yaling Han.;Bimmer E Claessen.;Shao-Liang Chen.;Qiu Chunguang.;Yujie Zhou.;Yawei Xu.;Lin Hailong.;Jiyan Chen.;Wu Qiang.;Ruiyan Zhang.;Suxin Luo.;Yongjun Li.;Jianhua Zhu.;Xianxian Zhao.;Xiang Cheng.;Jian'an Wang.;Xi Su.;Jianhong Tao.;Yingxian Sun.;Geng Wang.;Yi Li.;Liya Bian.;Ridhima Goel.;Samantha Sartori.;Zhongjie Zhang.;Dominick J Angiolillo.;David J Cohen.;C Michael Gibson.;Adnan Kastrati.;Mitchell Krucoff.;Shamir R Mehta.;E Magnus Ohman.;Philippe Gabriel Steg.;Yuqi Liu.;George Dangas.;Samin Sharma.;Usman Baber.;Roxana Mehran.
来源: Circ Cardiovasc Interv. 2022年15卷4期e009495页
The risk/benefit tradeoff of dual antiplatelet therapy after percutaneous coronary intervention may vary in East Asian patients as compared with their non-East Asian counterparts.
414. Short-Term Postoperative Use of Rivaroxaban to Prevent Radial Artery Occlusion After Transradial Coronary Procedure: The RESTORE Randomized Trial.
作者: Dongjie Liang.;Qingcheng Lin.;Qianli Zhu.;Xiaodong Zhou.;Ying Fang.;Liangguo Wang.;Guangze Xiang.;Kenneth I Zheng.;Weijian Huang.;Peiren Shan.
来源: Circ Cardiovasc Interv. 2022年15卷4期e011555页
Adequate procedural anticoagulation is crucial for radial artery occlusion (RAO) prevention in patients undergoing transradial access coronary catheterization, although the effect of postprocedural anticoagulation lack thorough investigation. The aim of this study was to evaluate the clinical value of short-term postoperative anticoagulation with rivaroxaban for 24 hours and 1-month RAO prevention in patients who received transradial coronary procedures.
415. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.
作者: Ratika Parkash.;George A Wells.;Jean Rouleau.;Mario Talajic.;Vidal Essebag.;Allan Skanes.;Stephen B Wilton.;Atul Verma.;Jeffrey S Healey.;Laurence Sterns.;Matthew Bennett.;Jean-Francois Roux.;Lena Rivard.;Peter Leong-Sit.;Mats Jensen-Urstad.;Umjeet Jolly.;Francois Philippon.;John L Sapp.;Anthony S L Tang.
来源: Circulation. 2022年145卷23期1693-1704页
Atrial fibrillation (AF) and heart failure (HF) frequently coexist and can be challenging to treat. Pharmacologically based rhythm control of AF has not proven to be superior to rate control. Ablation-based rhythm control was compared with rate control to evaluate if clinical outcomes in patients with HF and AF could be improved.
416. Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study.
作者: Ka-Chun Li.;Liping Huang.;Maoyi Tian.;Gian Luca Di Tanna.;Jie Yu.;Xinyi Zhang.;Xuejun Yin.;Yishu Liu.;Zhixin Hao.;Bo Zhou.;Xiangxian Feng.;Zhifang Li.;Jianxin Zhang.;Jixin Sun.;Yuhong Zhang.;Yi Zhao.;Ruijuan Zhang.;Yan Yu.;Nicole Li.;Lijing L Yan.;Darwin R Labarthe.;Paul Elliott.;Yangfeng Wu.;Bruce Neal.;Thomas Lung.;Lei Si.
来源: Circulation. 2022年145卷20期1534-1541页
SSaSS (Salt Substitute and Stroke Study), a 5-year cluster randomized controlled trial, demonstrated that replacing regular salt with a reduced-sodium, added-potassium salt substitute reduced the risks of stroke, major adverse cardiovascular events, and premature death among individuals with previous stroke or uncontrolled high blood pressure living in rural China. This study assessed the cost-effectiveness profile of the intervention.
417. Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA.
作者: Daniel B Mark.;John A Spertus.;Robert Bigelow.;Sophia Anderson.;Melanie R Daniels.;Kevin J Anstrom.;Khaula N Baloch.;David J Cohen.;Claes Held.;Shaun G Goodman.;Sripal Bangalore.;Derek Cyr.;Harmony R Reynolds.;Karen P Alexander.;Yves Rosenberg.;Gregg W Stone.;David J Maron.;Judith S Hochman.; .
来源: Circulation. 2022年145卷17期1294-1307页
ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) compared an initial invasive treatment strategy (INV) with an initial conservative strategy in 5179 participants with chronic coronary disease and moderate or severe ischemia. The ISCHEMIA research program included a comprehensive quality-of-life (QOL) substudy.
418. Validating an Idiopathic Dilated Cardiomyopathy Diagnosis Using Cardiovascular Magnetic Resonance: The Dilated Cardiomyopathy Precision Medicine Study.
作者: Garrie J Haas.;Karolina M Zareba.;Hanyu Ni.;Erika Bello-Pardo.;Gordon S Huggins.;Ray E Hershberger.; .
来源: Circ Heart Fail. 2022年15卷5期e008877页
Coronary angiography to identify coronary artery disease has been foundational to distinguish the cause of dilated cardiomyopathy (DCM), including the assignment of idiopathic or ischemic cardiomyopathy. Late gadolinium enhancement (LGE) with cardiovascular magnetic resonance (CMR) has emerged as an approach to identify myocardial scar and identify etiology.
419. Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial.
作者: Steven A Lubitz.;Steven J Atlas.;Jeffrey M Ashburner.;Ana T Trisini Lipsanopoulos.;Leila H Borowsky.;Wyliena Guan.;Shaan Khurshid.;Patrick T Ellinor.;Yuchiao Chang.;David D McManus.;Daniel E Singer.
来源: Circulation. 2022年145卷13期946-954页
Undiagnosed atrial fibrillation (AF) may cause preventable strokes. Guidelines differ regarding AF screening recommendations. We tested whether point-of-care screening with a handheld single-lead ECG at primary care practice visits increases diagnoses of AF.
420. Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial.
作者: Tetsuro Yoshida.;Akihiro Nakamura.;Junichi Funada.;Mari Amino.;Wataru Shimizu.;Masayuki Fukuzawa.;Saori Watanabe.;Takuya Hayashi.;Takeshi Yamashita.;Ken Okumura.;Masaharu Akao.
来源: Circulation. 2022年145卷9期718-720页 |